ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Nov. 16, 2021)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report November 16, 2021, filed under Item 8.01, Other Events. It states that on November 16, 2021 the company posted an updated corporate presentation on the company's website, filed as Exhibit 99.1. The report includes a cautionary note that the presentation contains forward-looking statements about the likelihood of success (including safety and efficacy) and promise of the "pipeline", the planned initiation, design or completion of clinical trials, the ability to enroll subjects, manufacturing methods and technologies, and the current cash position. The signature block shows /s/ Joseph E. Payne, Chief Executive Officer.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2021

ARCTURUS THERAPEUTICS
HOLDINGS INC.

(Exact name of registrant as specified in its
charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number, including
area code: (858) 900-2660

(Former name or former address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Corporate Presentation

On November 16, 2021, the Company posted an updated
corporate presentation on its website. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Cautionary Note Regarding Forward-Looking Statements

The presentation contains forward-looking statements.
These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently
subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements
about: our strategy, future operations, collaborations, the likelihood of success (including safety and efficacy) and promise of our pipeline,
the planned initiation, design or completion of clinical trials, anticipated sponsorship and/or funding of clinical trials of our candidates,
the likelihood that we will obtain clearance from regulatory authorities to proceed with planned clinical trials, the ability to enroll
subjects in clinical trials, the likelihood that preclinical or clinical data will be predictive of future clinical results, the likelihood
that clinical data will be sufficient for regulatory approval or completed in time to submit an application for regulatory approval within
a particular timeframe, the anticipated timing for regulatory submissions, the timing of, and expectations for, any results of any preclinical
or clinical studies or regulatory approvals, the potential administration regimen or dosage, or ability to administer multiple doses of,
any of our drug candidates, our manufacturing methods and technologies (including purification, lyophilization and stability of our products),
the likelihood that a patent will issue from any patent application, our current cash position and adequacy of our capital to support
future operations, and any statements other than statements of historical fact.

In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,”
“plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,”
“potential” and similar expressions (including the negative thereof) intended to identify forward looking statements. Arcturus
may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking
statements such as the foregoing, and you should not place undue reliance on such forward-looking statements. The forward-looking statements
contained or implied in the presentation are subject to other risks and uncertainties, including those discussed under the heading “Risk
Factors” in Arcturus’ most recent Annual Report on Form 10-K with the SEC and in other filings that Arcturus makes with the
SEC. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
99.1 | Presentation dated November 16, 2021
104 | Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: November 16, 2021
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2021-11-16_0001193805-21-001584.htm

Size

25,945 bytes

SHA-256

be479348f19d2a58811ce964f108c0a9f8cebaf1acbc45d6da446e237cfe31c6

Our copy

SEC_ARCT_8-K_filed2021-11-16_0001193805-21-001584.htm

Original

www.sec.gov